Evidence map›Paper›PMID 21504410›Full record

ReviewCurrent pharmaceutical design2011

Drug discovery of antimicrobial photosensitizers using animal models.

Sulbha K Sharma, Tianhong Dai, Gitika B Kharkwal, Ying-Ying Huang, Liyi Huang, Vida J Bil De Arce, George P Tegos, Michael R Hamblin

Abstract readReview
In one paragraph

Review in Current pharmaceutical design, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 104 citations in OpenAlex.

  1. Cationic Bacteriochlorin in the photodynamic inactivation of microorganisms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. The Role of Porphyrinoid Photosensitizers for Skin Wound Healing.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Journal of thoracic disease · 2019
    Article
  16. Article
  17. Nonconventional Therapeutics againstMicrobiology spectrum · 2018
    Article
  18. Review
  19. Progressive cationic functionalization of chlorin derivatives for antimicrobial photodynamic inactivation and related vancomycin conjugates.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2018
    Article
  20. The Effect of Quorum-Sensing and Efflux Pumps Interactions inJournal of lasers in medical sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sulbha K SharmaWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Tianhong Dai
Gitika B Kharkwal
Ying-Ying Huang
Liyi Huang
Vida J Bil De Arce
George P Tegos
Michael R Hamblin
Massachusetts General Hospital · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
New Stereoregular Functionalized Fullerenes as Nanomedicines for PDTR01CA137108 · NCI · UNIVERSITY OF MASSACHUSETTS LOWELL · PI CHIANG, LONG Y. · 2009 to 2012
$1.3M
NCI NIH HHS R01 CA137108NCI NIH HHS R01CA137108NIAID NIH HHS R01 AI050875NIAID NIH HHS R01CA/AI838801PHS HHS R01A1050875
6 · The paper itself

Abstract

Antimicrobial photodynamic therapy (aPDT) is an emerging alternative to antibiotics motivated by growing problems with multi-drug resistant pathogens. aPDT uses non-toxic dyes or photosensitizers (PS) in combination with harmless visible of the correct wavelength to be absorbed by the PS. The excited state PS can form a long-lived triplet state that can interact with molecular oxygen to produce reactive oxygen species such as singlet oxygen and hydroxyl radical that kill the microbial cells. To obtain effective PS for treatment of infections it is necessary to use cationic PS with positive charges that are able to bind to and penetrate different classes of microbial cells. Other drug design criteria require PS with high absorption coefficients in the red/near infra-red regions of the spectrum where light penetration into tissue is maximum, high photostability to minimize photobleaching, and devising compounds that will selectively bind to microbial cells rather than host mammalian cells. Several molecular classes fulfill many of these requirements including phenothiazinium dyes, cationic tetrapyrroles such as porphyrins, phthalocyanines and bacteriochlorins, cationic fullerenes and cationic derivatives of other known PS. Larger structures such as conjugates between PS and cationic polymers, cationic nanoparticles and cationic liposomes that contain PS are also effective. In order to demonstrate in vivo efficacy it is necessary to use animal models of localized infections in which both PS and light can be effectively delivered into the infected area. This review will cover a range of mouse models we have developed using bioluminescent pathogens and a sensitive low light imaging system to non-invasively monitor the progress of the infection in real time. Effective aPDT has been demonstrated in acute lethal infections and chronic biofilm infections; in infections caused by Gram-positive, Gram-negative bacteria and fungi; in infections in wounds, third degree burns, skin abrasions and soft-tissue abscesses. This range of animal models also represents a powerful aid in antimicrobial drug discovery.

Indexed as

AnimalsAnti-Infective AgentsBacterial InfectionsDisease Models, AnimalDrug DesignDrug Resistance, MicrobialDrug Resistance, MultipleHumansMiceMycosesPhotochemotherapyPhotosensitizing AgentsReactive Oxygen SpeciesAnti-Infective AgentsPhotosensitizing AgentsReactive Oxygen Species

Identifiers

PMID21504410
PMCPMC3463379
OpenAlexW2148866763

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.